These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26028995)

  • 1. Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer.
    Punnen S; Pavan N; Parekh DJ
    Rev Urol; 2015; 17(1):3-13. PubMed ID: 26028995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices.
    Konety B; Zappala SM; Parekh DJ; Osterhout D; Schock J; Chudler RM; Oldford GM; Kernen KM; Hafron J
    Rev Urol; 2015; 17(4):231-40. PubMed ID: 26839521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
    Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
    Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information.
    Zappala SM; Dong Y; Linder V; Reeve M; Sjoberg DD; Mathur V; Roberts R; Okrongly D; Newmark J; Sant G; Steiner M
    Int J Clin Pract; 2017 Jun; 71(6):. PubMed ID: 28497893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
    Assel M; Sjöblom L; Murtola TJ; Talala K; Kujala P; Stenman UH; Taari K; Auvinen A; Vickers A; Visakorpi T; Tammela TL; Lilja H
    Eur Urol Focus; 2019 Jul; 5(4):561-567. PubMed ID: 29137895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort.
    Lonergan PE; Vertosick EA; Assel M; Sjoberg DD; Haese A; Graefen M; Boorjian SA; Klee GG; Cooperberg MR; Pettersson K; Routila E; Vickers AJ; Lilja H
    BJU Int; 2021 Aug; 128(2):218-224. PubMed ID: 33306251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
    Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
    Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 4Kscore Predicts the Grade and Stage of Prostate Cancer in the Radical Prostatectomy Specimen: Results from a Multi-institutional Prospective Trial.
    Punnen S; Nahar B; Prakash NS; Sjoberg DD; Zappala SM; Parekh DJ
    Eur Urol Focus; 2017 Feb; 3(1):94-99. PubMed ID: 28720374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of 4Kscore as a Secondary Test Before Prostate Biopsy: Impact on US Population Trends for Prostate Cancer.
    Scuderi S; Tin A; Gandaglia G; Stabile A; Montorsi F; Briganti A; Vickers AJ
    Eur Urol Open Sci; 2023 Jun; 52():1-3. PubMed ID: 37182119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.
    Parekh DJ; Punnen S; Sjoberg DD; Asroff SW; Bailen JL; Cochran JS; Concepcion R; David RD; Deck KB; Dumbadze I; Gambla M; Grable MS; Henderson RJ; Karsh L; Krisch EB; Langford TD; Lin DW; McGee SM; Munoz JJ; Pieczonka CM; Rieger-Christ K; Saltzstein DR; Scott JW; Shore ND; Sieber PR; Waldmann TM; Wolk FN; Zappala SM
    Eur Urol; 2015 Sep; 68(3):464-70. PubMed ID: 25454615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: Overall cost savings and improved quality of care to the us healthcare system.
    Voigt JD; Dong Y; Linder V; Zappala S
    Rev Urol; 2017; 19(1):1-10. PubMed ID: 28522924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial.
    Josefsson A; Månsson M; Kohestani K; Spyratou V; Wallström J; Hellström M; Lilja H; Vickers A; Carlsson SV; Godtman R; Hugosson J
    Eur Urol; 2024 Sep; 86(3):223-229. PubMed ID: 38772787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results.
    Zappala SM; Scardino PT; Okrongly D; Linder V; Dong Y
    Rev Urol; 2017; 19(3):149-155. PubMed ID: 29302237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.
    Maccini MA; Westfall NJ; Van Bokhoven A; Lucia MS; Poage W; Maroni PD; Wilson SS; Glodé LM; Arangua P; Newmark J; Steiner M; Werahera PN; Crawford ED
    Prostate; 2018 May; 78(7):506-511. PubMed ID: 29460452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men.
    Punnen S; Freedland SJ; Polascik TJ; Loeb S; Risk MC; Savage S; Mathur SC; Uchio E; Dong Y; Silberstein JL
    J Urol; 2018 Jun; 199(6):1459-1463. PubMed ID: 29223389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine.
    Fredsøe J; Rasmussen M; Tin AL; Vickers AJ; Borre M; Sørensen KD; Lilja H
    Sci Rep; 2022 Sep; 12(1):15193. PubMed ID: 36071094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of high-grade prostate cancer risk using prostate cancer biomarkers.
    Stanton WN; Crawford ED; Arangua PB; La Rosa FG; van Bokhoven A; Lucia MS; Poage WL; Partin A; Maroni P; Werahera PN
    Can J Urol; 2020 Feb; 27(1):10080-10085. PubMed ID: 32065862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance.
    Borque-Fernando Á; Rubio-Briones J; Esteban LM; Dong Y; Calatrava A; Gómez-Ferrer Á; Gómez-Gómez E; Gil Fabra JM; Rodríguez-García N; López González PÁ; García-Rodríguez J; Rodrigo-Aliaga M; Herrera-Imbroda B; Soto-Villalba J; Martínez-Breijo S; Hernández-Cañas V; Soto-Poveda AM; Sánchez-Rodríguez C; Carrillo-George C; Hernández-Martínez YE; Okrongly D
    Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):84-90. PubMed ID: 30108375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
    Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.